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Background: Depression is a highly prevalent disorder that is one of the leading causes of disability world-
wide. Despite an unknown aetiology, evidence suggests that the innate and adaptive immune systems play a
significant role in the development and maintenance of major depressive disorder (MDD). The non-competi-
tive glutamatergic N-methyl-D-aspartate receptor (NMDAR) antagonist, (R,S)-ketamine (ketamine), has
demonstrated rapid and robust efficacy as an antidepressant when administered at sub-anaesthetic doses.
Methods: Our goal was to characterize the pro-inflammatory profile of patients with MDD by measuring pro-
inflammatory cytokines in plasma and circulating monocyte subsets and to understand how ketamine indu-
ces an anti-inflammatory program in monocyte and macrophages in vitro and vivo.
Finding: Our results show that patients with MDD without other comorbidities (N = 33) exhibited significantly
higher levels of pro-inflammatory IL-12 and IL-6 in plasma and that these cytokines were associated with increased
numbers of non-classical (CD11b+CD16brightCD14neg) monocytes and increased activation state (CD40+CD86+) of
classical monocytes in circulation. Remarkably, we have demonstrated that sub-anaesthetic doses of ketamine pro-
grams humanmonocytes intoM2c-likemacrophages by inducing high levels of CD163 andMERTKwith intermedi-
ate levels of CD64 and stimulating mTOR-associated gene expression in vitro. The NMDAR antagonist MK-801, but
not the a-amino-3‑hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) antagonist, NBQX, also polar-
izes macrophages to an M2c-like phenotype, but this phenotype disappears upon mTOR pathway inhibition. Sub-
anaesthetic doses (10mg/kg) of ketamine administration in mice both promote reduction of circulating classical
pro-inflammatorymonocytes and increase of alternativeM2macrophage subtypes in the spleen and CNS.
Interpretation: Our results suggest an anti-inflammatory property of ketamine that can skew macrophages to
an M2-like phenotype, highlighting potential therapeutic implications not only for patients with MDD but
also other inflammatory-based diseases.
Funding: This study was supported by grants from the Consejo Nacional de Investigaciones Científicas y
Tecnicas (CONICET) and Agencia Nacional de Promocion Científica y Tecnologica (ANPCyT-FONCYT).
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
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Evidence before this study
Major depressive disorder (MDD) is a prevalent and debilitating
disorder in which treatment often results inadequate in approxi-
mately two-thirds of patients. The increasing involvement of
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last two to three decades, has provided new potential therapeutic
avenues. MDD patients exhibited all cardinal features of inflam-
mation, including increased circulating levels of inflammatory
cytokines, chemokine, and activated immune cells. The discovery
of the rapid-acting antidepressants effects of ketamine has opened
a new opportunity to develop a novel class of safe and effective
therapy for MDD. The mechanistic action of ketamine on CNS has
extensively explored. However, it is not entirely understood how
ketamine impacts on the activation and polarization program of
macrophages. This is a critical aspect considering the inflamma-
tory bias as an aetiological factor for MDD.
Added value of this study
Our results contribute to understanding better some cellular
and cytokine players associated with MDD. We observed a
clear correlation between the increased proportion of non-
classical monocyte and pro-inflammatory cytokines (IL-6 and
IL-12) levels. But interestingly not all patients have shown
high cytokine levels or a pro-inflammatory cellular profile.
Increased activation of CD86 and CD40 markers were also
observed in the classical subset. Additionally, we have demon-
strated how ketamine primes monocytes to initiate an anti-
inflammatory program in vitro via NMDA receptor and mTOR
signalling dependency. Finally, we also show that an in vivo
administration of sub-anaesthetic doses of ketamine promotes
an anti-inflammatory macrophage skewing in CNS and spleen.
Implications of all the available evidence
There still are controversial opinions in regard to inflammatory
players, treatment and particularly to determine causality in
human patients with MDD. So, measurements with several
immune markers and longitudinal prospective study are
needed to identify depression-specific biomarkers that will also
allow better immunotherapeutic treatment strategies.
1. Introduction
Depression is a highly prevalent and disabling disease that com-
prises a set of pleomorphic syndromes with emotional, cognitive, vis-
ceral, and behavioural symptoms domains. According to the World
Health Organization, over 350 million people worldwide suffer from
depression [1], and the Global Burden of Disease Study revealed that
Major Depressive Disorder (MDD) is one of the leading causes of the
global burden of disease [2].
Despite the public impact of depression, its aetiology remains
unknown. However, in recent years, a compelling body of evidence
has emerged suggesting the role of the innate and adaptive immune
systems in the development and maintenance of MDD. Patients with
MDD exhibit cardinal features of an inflammatory response, such as
increased levels of pro-inflammatory cytokines and their receptors
along with increased release of acute-phase reactants, chemokine,
and soluble adhesion molecules in peripheral blood and cerebrospi-
nal fluid [35]. Additionally, higher levels of inflammation appear to
increase the risk for the development of de novo depression [6]. Cyto-
kines can induce depressive-like behaviours; in studies where
healthy participants are given endotoxin infusions to trigger release
of inflammatory cytokines, classical depressive symptoms emerge.
Exogenous cytokine infusions also cause the classical phenotypic
behavioural and cognitive features of depression [4,5,7].
Monocyte-macrophage lineage cells are multifunctional and found in
nearly all tissues throughout the body. They orchestrate the initiation and
resolution phases of both innate and adaptive immunity, significantlyPlease cite this article as: W. Nowak et al., Pro-inflammatory monocy
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damage [8,9]. Circulating monocytes, the precursors of macrophages,
migrate across the vascular endothelium to peripheral tissues where they
mature into macrophages and adopt different activation states.
Previous studies by Carvalho et al. [10] and Grosse et al. [11] have
highlighted the pro-inflammatory state of circulating sorted CD14+
monocytes in patients with MDD. However, new gene expression
studies in human monocyte biology emphasise the importance of
defining the roles of monocytes populations in circulation based on
the expression of CD14 and CD16 [12,13]. The CD16+ subset can be
further segregated into two subpopulations: the intermediate subset
that expresses CD16 coupled with CD14 (CD14+ CD16+), and the non-
classical subset that expresses high levels of CD16 with low levels of
CD14 (CD14neg CD16bright). The third subset that constitutes approxi-
mately 8590% of circulating monocytes in human peripheral blood
expresses high levels of CD14 with no CD16 expression, and is
termed classical monocytes (CD14bright CD16neg). It has been demon-
strated that the three subsets of monocytes circulate in dynamic
equilibrium, with 99% of classical monocytes leaving the circulation
and the remaining 1% becoming intermediate monocytes, 100% of
which then mature in the circulation to become non-classical mono-
cytes under steady state conditions [14]. Moreover, non-classical
monocytes have been proposed to act as custodians of vasculature by
maintaining endothelial cells integrity [14,15]. Additionally, several
studies have shown that circulating CD16+ monocytes are found in
large numbers in patients with inflammatory processes and infec-
tious diseases [1618].
Macrophages assume critical roles in almost every tissue and disease
state through their ability to adopt distinct functional capacities in differ-
ent microenvironments [19]. A major goal of the macrophage field is to
link specific functions with specific cellular andmolecular pathways asso-
ciated with different macrophage activation profiles. Although macro-
phage polarization is not a fixed state due to the plasticity and ability of
these cells to integratemultiple signals, twomajor groups are the classical
pro-inflammatory M1 and the regulatory and tissue repair M2 macro-
phages that capture a snapshot of the inflammatory milieu at a specific
point in time and space [9,20]. Pro-inflammatory M1s are characterized
by strong induction of pro-inflammatory cytokines, such as TNFa, IL-6,
IL-1b, and IL-12, high expression of CD64 and low levels of CD206 and
CD163, all of which are necessary for pathogen clearance. High levels of
CD206, CD163, and MERTK expression characterize the anti-inflamma-
tory M2 repertoire of macrophages that are involved in tissue repair and
regulatory function [9,20,21]. Additional details about the polarization
phenotypemarkers used in this study can be found in Table S1.
The high prevalence and burden associated with MDD is partially
explained by the lack of efficacy of available treatments. Studies pub-
lished during the last decade showed that the magnitude of the effect
of antidepressants has been overestimated for many years. One third
of patients with MDD did not achieve remission despite multiple tri-
als using different types of antidepressants [22]. Moreover, as a result
of selective reporting, the effect size achieved with antidepressants is
almost one third less than that reported in published data [23], which
has led to the search of new therapeutic targets for the development
of antidepressant drugs. This search identified the non-competitive
glutamatergic N-methyl-D-aspartate receptor (NMDAR) antagonist,
(R,S)-ketamine (ketamine), which has demonstrated rapid and robust
efficacy as an antidepressant by improving core depressive symp-
toms including depressed mood, anhedonia, and suicidal thoughts in
treatment-refractory unipolar and bipolar depressed patients when
administered at sub-anaesthetic doses. Remarkably, these actions are
observed within hours following a single administration and per-
sisted for approximately 7 days with a single infusion [3,2426].
The mechanism by which ketamine elicits a rapid decrease in
depressive symptoms does not appear to be explained entirely by its
antagonizing effect on neuronal NMDAR alone since its half-life is
approximately three hours while the antidepressant effect lasts forte profile in patients with major depressive disorder and suicide
ages by NMDAR and mTOR, EBioMedicine (2019), https://doi.org/
Table 1
Demographics and clinical characteristics of
patients with MDD and suicide behaviour (n = 33).
Characteristic n (%)*
Age (yr), mean (SD) 36.36 (12.75)
Sex
Men 8 (24.20)
Women 25 (75.80)
Marital status
Partnership/cohabiting 27 (81.80)
Separated/divorced 6 (18.20)
Height (m), mean (SD) 1.64 (0.99)
Weight (kg), mean (SD) 66.83 (14.97)
BMI, mean (SD) 24.58 (3.27)
Education (yr), mean (SD) 11.33 (3.18)
Suicide behaviour
SI 8 (24.2)
SA 25 (75.8)
Lethality index SA
Very low 9 (36)
Low 9 (36)
High 7 (28)
Age at first SA (yr), mean (SD) 23.88 (13.75)
Previous SA
No 11 (66.6)
Yes 22 (33.3)
Psychiatric treatment history
No 14 (42)
Yes 19 (58)
Receiving medications
No 14 (42)
Yes 19 (58)
Type of medications
Antidepressants 13 (68)
Mood stabilizers 6 (32)
Antipsychotics 12 (63)
Benzodiazepines 18 (94)
Other 1 (5)
SD=standard deviation; m=metre; kg=kilogram;
BMI=Body Mass Index; yr=year; SI=suicide idea-
tion; SA=suicide attempt; lethality index SA=le-
thality of the index (ie, suicide attempt that
resulted in hospitalization at study enrolment) sui-
cide attempt.
* unless otherwise specified.
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mediates the antidepressant response but rather synaptic plasticity
mechanisms caused by ketamine that are involved in the longer term
behavioural effects. While it has been suggested that ketamine has
anti-inflammatory properties, results in previous studies conducted
in humans and animals have been inconsistent [2729]. However, a
recent clinical study has shown a positive correlation between
changes in cytokine levels after ketamine infusion and improvement
in depressive symptoms with treatment-resistant depression [30].
We hypothesized that ketamine induces an anti-inflammatory
program in macrophages that contribute to the rapid and sustained
anti-depressant effect. In order to test this hypothesis, we evaluated
the major cellular and cytokine inflammatory profile in patients with
MDD and the effect of ketamine on macrophage programming during
macrophage differentiation and polarization in vitro and in vivo.
2. Material and methods
2.1. Patients
The present exploratory analysis used data and blood samples
obtained from patients enroled in amulticenter prospective cohort study
conducted in Buenos Aires, Argentina. The cohort recruited patients who
had been admitted to the emergency department of psychiatric hospitals
for current suicidal ideation or a recent suicide attempt. Eligible study
participants were aged 1865 years, hospitalized for a suicide attempt
within 48 h, and had a diagnosis of MDD. Exclusion criteria included an
inability to respond autonomously (ie, due to sedative effects of medica-
tion or language limitations), met DSM-IV diagnostic criteria for sub-
stance abuse, or presence of a medical illness. Baseline characteristics
along with clinical and psychopharmacology treatment of patients with
MDD were collected and summarized in Table 1. Any additional clinical
illnesses were reported at the screening interview, and no medications
beyond the psychopharmacological treatments were allowed.
The control group (N = 20) consisted of gender and age-matched
individuals (25% men & 75% women, with a median age of 34.5 years
old and a SD of 5.3) who had not taken any medication.
2.2. Ethics statement
All participants gave written informed consent to participate in
the study. The study protocol was approved by the institutional
review board at each participating hospital. The present analysis
included 33 patients recruited between May 2015 and March 2017
who met DSM-IV diagnostic criteria for MDD. Patients were evalu-
ated by specialized psychiatrists through semi-structured clinical
psychiatric interviews, which included specific questions about clini-
cal and demographic variables. The Mini International Neuropsychi-
atric Interview (MINI) [31] was used for diagnostic purposes. At the
end of the assessment, blood samples were collected into EDTA-
coated tubes (BD, Vacutainer) and transported to the laboratory.
2.3. Peripheral blood mononuclear cells (PBMCs) isolation and
characterization of monocyte subsets by flow cytometry
Plasma and PBMCs from patients with MDD and healthy volunteer
controls (HC) were obtained by centrifugation as previously described
[32]. The plasma fractionwas preserved at80 °C for cytokinemeasure-
ment. PBMCs were isolated by density gradient centrifugation employ-
ing Ficoll Paque Plus (GE Healthcare Cat# 17144003), cryopreserved in
90% foetal bovine serum (FBS, Gibco Cat # 10091148) plus 10% dimethyl
sulfoxide (Sigma Aldrich, St. Louis, MO, USA), and stored in liquid nitro-
gen until use. Monocyte subsets were analysed from cryopreserved
PBMCs. Briefly, cells were thawed, washed, and blocked in 1x PBS + FBS
2% on ice for 30 min. Cells were then washed with 1x PBS + FBS 2% and
incubated for 30 min on ice with appropriate antibody combinationsPlease cite this article as: W. Nowak et al., Pro-inflammatory monocy
behaviour and how ketamine induces anti-inflammatory M2 macroph
10.1016/j.ebiom.2019.10.063against human CD11b-allophycocyanin/Cy7 (APC)/Cy7) (BioLegend Cat
# 101225, RRID: AB_830,641), CD14-PE (BioLegend Cat # 325605, RRID:
AB_830678) CD16-fluorescein isothiocyanate (FITC) (BioLegend Cat #
302005, RRID: AB_314205), CD40-PECy7 (BioLegend Cat # 334321,
RRID: AB_10643414), and CD86 biotin (BioLegend Cat # 305404, RRID:
AB_314524) plus DyLightTM 649-conjugated Streptavidin (BioLegend
Cat # 405224). Live cells were distinguished using Fixable Viability Dye
eFluorTM 450 (eBioscience Cat # 65-0863-14). After staining, cells were
fixed with Cytofix/Cytoperm kit (BD Bioscience Cat# 554714) and
acquired using a FACS Canto I (Becton Dickinson). All analysis was car-
ried out with FlowJo software (Tree Star).
2.4. In vitro lipopolysaccharide (LPS) stimulation of PBMCs
2.5£ 105 PBMCs from patients with MDD or HC were seeded in 96-
well plates with RPMI 1640 (Gibco Cat # 11875119) supplemented with
10% FBS and 1% penicillin-streptomycin (PS) (Sigma Aldrich). Cells were
stimulated with E. coli-derived LPS (110 ng/mL; O111:B4, Sigma
Aldrich Cat # L3024) and cultured in a humidified incubator at 37 °C
with CO2 (5%) for 24 h. Supernatants were collected at indicated time
points and stored at80 °C for cytokine measurements.
2.5. In vitro differentiation and stimulation of human macrophages
CD14+ monocytes were isolated from PBMCs using the EasySepTM
Human CD14 positive selection kit (StemCell Tech Cat # 18058)te profile in patients with major depressive disorder and suicide
ages by NMDAR and mTOR, EBioMedicine (2019), https://doi.org/
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was performed by plating 2.5£ 105 CD14+ monocytes in 48-well
plates containing 500 mL of RPMI 1640 supplemented with 10% FBS
and
1% PS. On day 5 of culture, the following reagents were added for an
additional 2 days of culture for macrophage polarization: LPS
(1 ng/mL) plus IFNg (50 ng/mL) for M1, IL-4 (40 ng/mL) for M2a, and
dexamethasone (0.1mM) for M2c. Recombinant cytokines were pur-
chased from R&D Systems (Cat # 285-IF for IFNg and Cat # 204-IL for
IL-4) and dexamethasone from Sigma Aldrich (Cat # D4902).
Ketamine-derived macrophages were obtained by adding (R,S)-
ketamine hydrochloride (Cost, Fada Pharma, Argentina) from day 0,
at indicated concentrations, and analysed after 7 days by flow cytom-
etry. Response to LPS was evaluated by challenging macrophages
with 1 ng/mL of LPS for additional 24 h. NMDA selective receptor
antagonist, (+)-MK-801 hydrogen maleate (Sigma Aldrich Cat #
M107), AMPA selective receptor antagonist NBQX hydrate (Sigma
Aldrich Cat # N171) or mTOR inhibitor rapamycin (Apexbio Technol-
ogy Cat # A8167) were also added to the culture from day 0 at the
indicated concentrations.
On day 7 of macrophage culture, supernatants were collected and
stored at 80 °C for cytokine measurement, and macrophages were
harvested by 15min incubation with 1x PBS + FBS 2% + 1mM ethyle-
nediaminetetraacetic acid (EDTA) from Sigma Aldrich (St. Louis, MO,
USA) on ice followed by gentle pipetting detachment from the bot-
tom of the well. Macrophages were then washed twice with 1x
PBS + FBS 2% to remove the EDTA.
The phenotype and activation of macrophages were characterized by
cell surface staining employing the appropriate combination of directly
conjugated antibodies against human CD11b-APC/Cy7 (BioLegend Cat #
101225, RRID: AB_830641), CD64-PE/Cy7 (BioLegend Cat # 305021,
RRID: AB_2561583), CD163-PerCP/Cy5.5 (BioLegend Cat # 333625, RRID:
AB_2,650629), CD206-AlexaFluor 488 (BioLegend Cat # 321113, RRID:
AB_571874), CD14-PE (BioLegend Cat # 325605, RRID: AB_830678), HLA-
DR-FITC (BioLegend Cat # 980402, RRID: AB_2616625), CD80-PE (BioLe-
gend Cat # 305207, RRID: AB_314,503), and MERTK-APC (R&D Systems
Cat # FAB8912A RRID:AB_357213) along with its control isotype IgG1-
APC (R&D Systems, Cat # IC002A). Viability was assessed with Fixable
Viability Dye eFluor 450 (e-Bioscience, Cat # 65-0863-14). After washing,
cells were fixed with Cytofix/Cytoperm kit (BD Bioscience, Cat # 554714).
Cells were acquired using a FACS Canto I cytometre (Becton Dickinson),
and all analysis was carried out with FlowJo software (Tree Star). The
fluorescence minus one (FMO) controls were used to set negative signal
in each interested channel.
2.6. Enzyme linked immunosorbent assay (ELISA)
Plasma levels of IL-6 (e-Bioscience Cat # BMS213HS) and IL-12 (e-
Bioscience Cat # BMS238HS) were detected with high sensitivity pre-
coated ELISA kits while TNFa (Cat # 88-7346, RRID: AB_2575093), IL-6
(Cat # 887066, RRID: AB_2574993), and IL-10 (Cat# 88-7106; RRID:
AB_2575001) levels in culture supernatants were assessed with ELISA
Ready-SET-Go kits (e-Bioscience) according to manufacturer’s protocol.
2.7. Intracellular cytokine measurement
2.5£ 105 PBMCs were seeded in 96-well plates with RPMI 1640
(Gibco Cat # 11875119) supplemented with 10% FBS and 1% PS
(Sigma Aldrich) and incubated with monensin (Golgistop; BD Bio-
sciences Cat # 554715) for 5 h. After that, PBMCs were stained with
anti-CD11b APC/Cy7 (BioLegend Cat # 10,225, RRID: AB_830641)
anti-CD14-PerCP (BioLegend Cat # 325631, RRID: AB_2563327), anti-
CD16-FITC (BioLegend Cat # 302005, RRID: AB_314205). Live cells
were distinguished using Fixable Viability Dye eFluorTM 450 (eBio-
science Cat # 65-0863-14). After staining of surface markers, cells
were fixed and made permeable according to the manufacturer'sPlease cite this article as: W. Nowak et al., Pro-inflammatory monocy
behaviour and how ketamine induces anti-inflammatory M2 macroph
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Then, the cells were stained with anti-human IL-12-biotin (Thermo-
Fisher Cat # AHC7129, RRID: AB_2536290) plus PE-conjugated Strep-
tavidin (BioLegend Cat #405203), and acquired using a FACS Canto I
(Becton Dickinson). All analysis was carried out with FlowJo software
(Tree Star).
2.8. Quantitative PCR (qPCR)
For gene expression analysis, macrophages were differentiated for
5 days and different concentrations of ketamine (0.1, 1 and 10mM) or
validated polarizing stimuli were added for an additional 48 h. On
day 7 of culture, cells were washed and then harvested with Trizol
(Life Technologies Cat # 15596018) following manufacturer’s instruc-
tions. Reverse transcription was performed using 100 ng of RNA in
20ml of reaction volume by employing iScript cDNA synthesis kit
(Bio-Rad Cat # 4106228). qPCR reactions were assessed using 1ml of
cDNA in 10ml of reaction volume by employing Power SYBR Green
PCR Master Mix kit (Applied Biosystems Cat # A25741) and Applied
Biosystems 7500 equipment. Primers used in this study are listed in
Supplementary Table S2. The reaction was normalized to house-
keeping gene expression levels, the elongation factor eEF-1 alpha
(EEF1A1), and the specificity of the amplified products was checked
through analysis of dissociation curves.
2.9. Mice
Eight to nine-week old male C57BL/6 (B6) mice were provided by
the animal facility of the CIBICI (Centro de Investigaciones en Bioquí-
mica Clínica e Inmunología)-CONICET, Facultad de Ciencias Químicas
de la Universidad Nacional de Cordoba, and maintained in a specific
pathogen-free environment. Mouse experiments were performed
according to National Institutes of Health guidelines with approval of
the Institutional Animal Care and Use Committee.
2.10. In vivo ketamine administration and immune compartment
analysis
Ketamine (10mg/kg/mouse) or saline solution for control mice
was administered via intra-peritoneal injection [33]. After 72 h, ani-
mals were euthanized and peripheral blood, bone marrow, spleens,
and brains were collected.
Mouse peripheral blood was obtained by cardiac puncture while
spleen cells and CNS leucocytes were isolated as previously described
[34]. Red blood cells were lysed with ACK lysing buffer (Gibco Cat #
A1049201); cells were then stained with appropriate antibody
cocktails against Alexa Fluor 647-CD11b (BioLegend Cat # 101220,
RRID: AB_493546), Ly-6G-APC/Cy7 (Biolegend Cat # 127623, RRID:
AB_10645331) and Ly-6C-PE/Cy7 (BioLegend Cat # 128017, RRID:
AB_1732093) for 30 min at room temperature and analysed by flow
cytometry. Cells were acquired in a FACS Canto II (Becton Dickinson).
All analysis was carried out with FlowJo software (Tree Star).
2.11. Murine blood leucocyte composition
Blood smears were prepared with one drop of blood obtained as
aforementioned, stained with May-Gr€unwald stain for 3 min, and
washed with water. The smear was then incubated with previously
prepared Giemsa (1 vol Giemsa + 9 vol water) for 15 min. Cells were
counted under optic microscope (Boeco, Germany).
2.12. Isolation of murine CNS immune cells
Briefly, mice were transcardially perfused with ice-cold 1x PBS,
and brains were collected in DMEM supplemented with sodium
pyruvate, penicillin, streptomycin, and glutamine cocktail (Gibco),te profile in patients with major depressive disorder and suicide
ages by NMDAR and mTOR, EBioMedicine (2019), https://doi.org/
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taining 3mg/mL collagenase D plus 10mg/mL DNAse (Sigma-
Aldrich). Then, CNS homogenates were filtered through 40mm pore
size cell strainers (BD Falcon), centrifuged at 1800 rpm and resus-
pended in 38% Percoll (GE Healthcare Cat # 17089101) before a
25 min centrifugation at 800 g without acceleration or brake. Myelin
and debris were discarded. Pelleted cells were washed and then
labelled with the following antibodies: CD45-APC/Cy7 (BioLegend
Cat # 368515, RRID: AB_2566375), CD11b-PE/Cy5 (BioLegend Cat #
101209, RRID: AB_312792), and F4/80-PE (BioLegend Cat # 123109,
RRID AB_893498). Fixable Viability Dye eFluor 450 (eBioscience Cat #
65-0863-14) was used according to manufacturer’s instructions to
distinguish live cells. After washing, cells were fixed with Cytofix/
Cytoperm kit (BD Bioscience Cat # 554714) and then stained with
Arginase-1-APC antibody (R&D Systems Cat # IC5868A).
2.13. Murine spleen cells flow cytometry
Spleen red blood cells were lysed with ACK lysing buffer (Gibco),
and cell viability was determined by Trypan blue exclusion staining
using a haemocytometre. Cells were then stained with CD11b-PE/Cy5
(BioLegend Cat # 101209, RRID: AB_312792) and F4/80-PE (BioLegend
Cat # 123109, RRID: AB_893498). Fixable Viability Dye eFluor 450
(eBioscience Cat# 65-0863-14) was used according to manufacturer’s
instructions to distinguish live cells. After washing, cells were fixed
with Cytofix/Cytoperm kit (BD Bioscience Cat # 554714) and then
stained with Arginase-1-APC antibody (R&D Systems Cat # IC5868A).
Cells were acquired using a FACS Canto II cytometre (Becton Dickin-
son), and all analysis was performed in FlowJo software (Tree Star).
2.14. Bone marrow derived macrophages (BMDM) differentiation and
stimulation
BMDMs were obtained from control and ketamine-treated mice
as previously described [35]. Briefly, cells were cultured in RPMI
1640 supplemented with 13% supernatant of the mouse L929 cell
line (conditioned medium) for 7 days. Then, cells were stimulated
with LPS (100 ng/mL) or maintained in media for 24 h. Cells were har-
vested and stained with CD86-APC/Cy7 (BioLegend Cat # 105,029,
RRID: AB_2074993), CD206-PE/Cy7 (BioLegend Cat # 141719, RRID:
AB_2562247), and CD36-PE (Biolegend Cat # 102605, RRID:
AB_389348) antibodies before analysis by flow cytometry with the
FACS Canto II cytometre (Becton Dickinson).
2.15. Statistical analysis
Data are expressed as mean § SEM. Two-tailed unpaired Students
t-test or one-way ANOVA test were used accordingly to determine
significance. When non-parametric Mann Whitney test was used, it
is denoted in figure legends. Correlation was assessed by Spearman
test. Statistical significance was set at p <0.05. Analysis was per-
formed using GraphPad Prism software.
3. Results
3.1. Elevated plasma levels of IL-12 strongly correlate with a higher
percentage of pro-inflammatory non-classical monocytes and more
activated classical monocytes in the blood of patients with MDD and
suicide behaviour
Inflammation has been associated with MDD in recent years
highlighting the critical role of the immune response in the patho-
physiology of this disease [3]. In a cohort of 33 patients with MDD
with no comorbidities, we found that 36% of patients (13/33) showedPlease cite this article as: W. Nowak et al., Pro-inflammatory monocy
behaviour and how ketamine induces anti-inflammatory M2 macroph
10.1016/j.ebiom.2019.10.063higher levels of IL-12 (> 0.1344 pg/mL) and 54% of patients (18/33)
had higher levels of IL-6 (> 0.9345 pg/mL) when compared with a
distribution of age- and gender-matched healthy controls (HC)
(Fig. 1a and b). Furthermore, 27% of patients with MDD (9/33) dem-
onstrated increased levels of both cytokines. The threshold for high
cytokine level was set as the mean value plus 1 SD of control group.
Taking into account that both cytokines are major pro-inflammatory
mediators secreted by activatedmonocytes, the three populations of cir-
culating classical (CD11b++CD16negCD14bright), non-classical (CD11b+
+CD16brightCD14neg), and the intermediate (CD11b++CD16+CD14+)
monocytes from HC and patients with MDD were analysed from PBMC
samples. Gating strategy is depicted in Supplementary Fig. S1 and repre-
sentative dot plots from HC and patients with MDD as well as colour
gates to discriminate the three monocytes subsets, denoted as blue
(classical), red (intermediate) and green (non-classical), are shown in
Fig. 1c and d.
We observed a significant reduction in the frequency of classi-
cal monocytes with a concomitant increase of the non-classical
and intermediate subsets in patients with MDD compared with HC
(Fig. 1eg). Interestingly, when patients with MDD were segre-
gated based on cytokine levels, a higher level of IL-12 (alone or
with IL-6) revealed a higher frequency of non-classical monocytes
(Fig. 1eg), and this association shows a strong positive correlation
(Fig. 1h). Even though a significant positive correlation of IL-6 and
increased non-classical monocytes was also observed (Fig. 1i),
patients with only high IL-6 do not show a significant increase of
this monocyte fraction, which may be explained by the co-pres-
ence of IL-12 in some samples of high IL-6. Patients with high lev-
els of only IL-6 or low levels of both cytokines denoted a clear
tendency of increased percentage of the intermediate monocyte
fraction, indicating that another cytokine could be involved.
Notably, classical monocytes from patients with MDD demon-
strate a higher activation state (measured as CD86+CD40+ cells)
and associated high levels of IL-6 or IL-12 than those from HC
(Fig. 1j and k). The increased activation state of classical mono-
cytes positively correlated with an increased frequency of non-
classical monocytes (Fig. 1l). In the same sense, a significantly
increased level of intracellular IL-12 was observed in the
CD11b+CD16negCD14bright subset of MDD patients at basal condi-
tion (Fig. 1m,n) underscoring that more activated classical mono-
cytes could be one of the sources of the increased IL-12 favouring
the transition to non-classical monocytes. Additionally, higher
production of IL-6 and IL-12 were found in the culture superna-
tant of PBMCs after 24 h of LPS treatment (Supplementary Fig. S2).3.2. Ketamine induces high levels of CD163 and MERTK expression and
intermediate levels of CD64 associated with M2c-like human
macrophages
Human circulating monocytes are the main source of macro-
phages that infiltrate tissues under inflammatory conditions or
stress. Here, we tested if sub-anaesthetic doses of ketamine affect
CD14+ monocyte differentiation and polarization into human mac-
rophages in comparison with classical M1 (IFNg plus LPS), M2a (IL-
4) and M2c (dexamethasone) in-vitro polarization. Interestingly,
we found that monocytes treated with ketamine from day 0 of cul-
ture acquired a M2c-like phenotype with increased levels of
MERTK and CD163 expression together with intermediate levels of
CD64, when compared with classical M1 and M2c profiles (Fig. 2a,
b and d). We did not observe changes in CD206, a classical M2a
marker (Fig. 2c). These results clearly demonstrate that ketamine
promotes an M2c-like macrophage.
Furthermore, we also discovered that ketamine-induced macro-
phages exhibit lower percentages of CD80+ and HLA-DR+ activationte profile in patients with major depressive disorder and suicide
ages by NMDAR and mTOR, EBioMedicine (2019), https://doi.org/
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Fig. 1. Increased plasma levels of IL-12 and IL-6 correlate with increased non-classical CD16brightCD14neg monocytes as well as with increased activation of classical CD16negCD14bright mono-
cytes in patients with MDD and suicide behaviour. Plasma levels of (a) IL-12p70 and (b) IL-6 in patients with MDD (n=33) and healthy controls (n=20) as determined by ELISA. Significant dif-
ferences between patients with MDD and healthy controls were calculated using a 2-tailed Mann-Whitney test (**p < 0.01). (c) Representative dot plots, after gating in mononuclear CD11b+
cells, showing the frequency of the three monocyte subsets based on CD14 vs. CD16 expression level in healthy controls and patients with MDD. Detailed gaiting strategy is shown in Supple-
mentary Fig. S1. (d) The threemonocytes subset are depicted as classical CD16negCD14bright (blue), non-classical CD16brightCD14neg (green) and intermediate CD16+CD14+ (red) for further anal-
ysis. Independent data are graphed in (e-g) showing decreased percentages of classical CD16negCD14bright monocytes alongside an increased percentage of non-classical CD16brightCD14neg
monocytes in peripheral blood of patients with MDD. The frequency of the three subpopulations of monocytes from the cohort of patients with MDD was also segregated based on IL-6 and
IL-12 plasma levels. The threshold for high cytokine level was set as the mean value plus 1 SD of control group. One-way ANOVA test was performed (**p < 0.01; ns p > 0.05). (h) and
(i) Increased plasma levels of IL-12 and IL-6 were positively correlated with the percentage of non-classical monocytes in the peripheral blood of patients withMDD and healthy controls. Cor-
relation was assessed by Spearman test. (j) Representative dot plots of CD86 and CD40 expression in classical monocyte subpopulations are shown. (k) Independent data showing percentage
of CD86+CD40+ classical monocytes in healthy controls and patients with MDD and, further segregated by IL-12 and IL-6 plasma levels. (l) Increased percentage of non-classical monocytes
was positively correlated with an increased percentage of CD86+CD40+ classical monocytes. One-way ANOVA testwas performed (***p< 0.001). Correlation was assessed by Spearman test. (m)
Representative dot plots showing the frequency of IL-12 positive cells after 5h of incubation with Golgi Stop and gating in CD11b+CD16negCD14bright subset. The Fluorescence Minus One
(FMO) was used to set positive staining. (n) Independent data showing the percentage of Il-12 positive cells in a healthy control group (n=8) and patients with MDD (n=13) and, further segre-
gated by IL-12 and IL-6 plasma levels. One-way ANOVA testwas performed (**p< 0.01; *p< 0.05). Patients were segregated as follows: MDD IL-12/6, high levels of both cytokines; MDD IL-12,
high levels of IL-12 only; MDD IL-6, patients high levels of IL-6 only; andMDD low, patients with similar levels of cytokines comparedwith healthy controls.
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W. Nowak et al. / EBioMedicine 00 (2019) 116 7markers (Fig. 2e and f) as well as reduced TNFa production (Fig. 2g)
when they were challenged with 1 ng/mL of LPS. Intriguingly, keta-
mine-induced macrophages already showed lower levels of IL-6
and IL-10 at baseline compared with untreated monocyte-derivedPlease cite this article as: W. Nowak et al., Pro-inflammatory monocy
behaviour and how ketamine induces anti-inflammatory M2 macroph
10.1016/j.ebiom.2019.10.063macrophages (Fig. 2h and i), supporting the phenotypic bias of keta-
mine-derived macrophages. After LPS stimulation, ketamine did not
modify IL-6 levels yet significantly reduced IL-10 level under the
same conditions (Fig. 2h and i).te profile in patients with major depressive disorder and suicide
ages by NMDAR and mTOR, EBioMedicine (2019), https://doi.org/
Fig. 2. Ketamine induces a M2c-like phenotype in monocyte-derived macrophages with increased levels of MERTK, CD163, and intermediate levels of CD64 while reducing the
response to LPS. Monocyte-derived macrophages were differentiated for 7 days in the presence or absence of ketamine (0.1, 1 and 10 mM), and the percentage of (a) MERTK, (b)
CD163, (c) CD206 and (d) CD64 positive CD11b+ macrophages was analysed by flow cytometry. Macrophage polarization controls were performed using dexamethasone (0.1 mM)
for M2c, IL-4 (40 ng/mL) for M2a, and LPS (1 ng/mL) plus IFN-g (50 ng/mL) for M1. Representative and independent data are shown. (e-i) To analyse the response to an inflammatory
stimulus, ketamine-induced macrophages were stimulated for 24h with 1 ng/mL of LPS. The activation markers (e) CD80 and (f) HLADR were evaluated by flow cytometry and (g)
TNF-a, (h) IL-6 and (i) IL-10 production was assessed by ELISA. Each dot represents an independent donor and pooled data were graphed. One-way ANOVA test was performed and
statistical significance is denoted as *p < 0.05; **p < 0.01; ***p < 0.001. Untreated condition: Untd; dexamethasone: DEX.
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W. Nowak et al. / EBioMedicine 00 (2019) 116 9Additionally, ketamine was able to dampen the macrophage acti-
vation markers (CD80 and HLA-DR) when these cells were pre-
treated for 30 min before LPS stimulation (Supplementary Fig. S3),
suggesting a rapid anti-inflammatory action of ketamine. Of note,
inherent donor variability was observed in some experiments either
during basal conditions or under treatment.Please cite this article as: W. Nowak et al., Pro-inflammatory monocy
behaviour and how ketamine induces anti-inflammatory M2 macroph
10.1016/j.ebiom.2019.10.0633.3. Ketamine up-regulates M2 gene expression profile including mTOR
pathway associated genes
Considering that ketamine induced an M2c-like phenotype in
macrophages, we compared the gene expression program primed by
ketamine versus the classical M1 (IFNg plus LPS), M2a (IL-4) and M2cte profile in patients with major depressive disorder and suicide
ages by NMDAR and mTOR, EBioMedicine (2019), https://doi.org/
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10 W. Nowak et al. / EBioMedicine 00 (2019) 116(dexamethasone) stimuli on human monocyte-derived macrophages.
We observed that ketamine induced a particular gene profile, with
higher levels of CCL22 and TGM2, two classical M2 genes (Fig. 3a and b).
We did not observe induction of IRF4 or the classical M1 genes IRF1
and CXCL10 (Fig. 3ce). On the other hand, we found that classical
mTOR pathway associated genes (SGK1, EIF4B, and FOXO1) were spe-
cifically up regulated after ketamine treatment (Fig. 3fh). Of note,
the SGK1 gene product is specifically involved downstream of
mTOR2 signalling and its expression is strictly transcriptionally and
post-transcriptionally regulated.3.4. Ketamine induces an M2 macrophage program through NMDAR
and mTOR pathways
In order to better understand if NMDAR and/or AMPAR are involved
in the M2c-like phenotype skewing by ketamine, we challenged mono-
cytes with the NMDAR antagonist, MK801 (110mM) and the AMPAR
antagonist NBQX (110mM) from day 0 of culture. We found that MK-
801 induced a similar macrophage polarization program as ketamine
treatment by augmenting MERTK but without modification in CD206
expression after 7 days of culture (Fig. 4a and b). On the other hand,
NBQX (110mM) did not induce MERTK but significantly increased
CD206 expression (Fig. 4a and b). Considering that NMDAR triggers the
mTOR pathway in CNS [33] and macrophage polarization depends on
mTOR complex activation [36], we blocked this complex during keta-
mine-induced macrophage differentiation and polarization. Monocyte-
derived macrophages differentiation in the presence of rapamycin
(0.11nM) significantly reduced the percentage of MERTK+, CD64+, and
CD163+ cells but increased the percentage of CD206 positive cells
(Fig. 4c). Therefore, the opposing effect of mTOR inhibition on MERTK
and CD206 expression clearly suggests a dichotomy on the pathway for
M2a andM2c polarization.3.5. Injection of sub-anaesthetic doses of ketamine modulates the
circulating myeloid compartment and promotes differentiation of anti-
inflammatory M2 macrophages in vivo
It has been demonstrated that injection of sub-anaesthetic doses
of ketamine (10mg/kg) improves the performance of mice stressed
by swimming test by activating mTOR signalling in the CNS [33].
Nonetheless, how ketamine affects or modulates the immune com-
partment in vivo has not been clarified. Here, we demonstrated that
intraperitoneal injection of sub-anaesthetic doses of ketamine in con-
trol mice significantly reduced the percentage of circulating pro-
inflammatory monocytes (CD11b+Ly6ChighLy6G) with a concomitant
increase in anti-inflammatory CD11b+Ly6Clow Ly6Gmonocytes after
72 h (Fig. 5a and b). Ketamine-treated mice did not show a significant
difference in total blood leucocyte numbers or percentage of cell
types, except for a significant increase of the eosinophil fraction (Sup-
plementary Fig. S4). However, the bone marrow and spleen of keta-
mine-treated mice showed increased cell numbers (Fig. 5c and d). On
the other hand, we observed a significant reduction of non-resident
macrophages (CD45highCD11b+F4/80+) in the CNS without changes in
the frequency of microglia (CD45lowCD11b+) (Fig. 5e and f). Strikingly,
these CD45highCD11b+F4/80+macrophages showed a significant
increase of the M2 effector enzyme (Arginase-1+) after 72 h of keta-
mine treatment (Fig. 5g). Similar results were observed in the spleens
of ketamine-treated mice in comparison with saline-treated mice
(Fig. 5h).
These results prompted us to evaluate if ketamine is capable of
reprogramming macrophages differentiation and polarization in
vitro. Remarkably, bone marrow progenitors from ketamine-treated
mice demonstrated clear skewing to M2 macrophage polarization
after 7 days of in vitro differentiation characterized by a lower per-
centage of CD86+CD206 cells and lower levels of CD36+ cells as wellPlease cite this article as: W. Nowak et al., Pro-inflammatory monocy
behaviour and how ketamine induces anti-inflammatory M2 macroph
10.1016/j.ebiom.2019.10.063as increased expression of CD206+CD86 fraction when stimulated
with LPS (Fig. 5ik).
4. Discussion
During the past two decades, an increasing body of evidence indi-
cates that the immune-inflammatory pathways and activation of
cell-mediated immunity are involved in the pathophysiology of
MDD. Maes et al. were the first to report that psychological stress and
stress-induced anxiety are related to a Th1-like response with
increased TNF-a, IL-6, IL-1 receptor antagonist, and IFNg production
in humans [37]. Classical depressive symptoms emerged when
healthy volunteers received endotoxin infusions to trigger the release
of inflammatory cytokines [7]. Furthermore, activation of peripheral
and/or central induced oxidative and nitrosative stress pathways
may explain co-occurrence of depression with a variety of inflamma-
tory disorders [38]. Even though increasing evidence shows that dif-
ferent types of psychosocial stressors may stimulate the pro-
inflammatory network, the source of inflammation remains unclear
[5]. The inflammation theory of depression involve a complex inter-
action of innate and adaptive immune cells, inflammatory cytokines,
endocrine signalling molecules, and neuromodulatory processes in
the periphery and the central nervous system that may have a pro-
found effect on behavioural alterations and the development of
depression [39,40]. An array of evidence using murine models has
implicated monocyte activation and pro-inflammatory cytokine
secretion in the increased traffic and infiltration to the brain, there-
fore contributing to the pathophysiology [4143]. Nowadays, the
opinions regarding the inflammatory players, causality, and treat-
ment for patients with MDD remain controversial. Measurements
with several immune markers are needed to identify depression-spe-
cific biomarkers that will also allow better immunotherapeutic treat-
ment strategies.
Our results demonstrate that patients with MDD presented elevated
plasma levels of inflammatory cytokines such as IL-6 and IL-12. The
increased IL-6 levels in our cohort is consistent with a recently pub-
lished meta-analysis compiling 42 studies in which patients with MDD
had higher IL-6 concentrations compared with HC. In the same meta-
analysis, only 4 studies evaluated the levels of IL-12 in patients with
MDD, and though levels of IL-12 were increased, these results were not
conclusive due to a high degree of heterogeneity [44]. However, in
agreement with our results, Kim et al. (not included in meta-analysis)
also found a significant increase of IL-12 levels in 34 patients with MDD
compared with HC [45]. Interestingly, increased levels of IL-12 have also
been detected in other inflammatory pathologies of the CNS such as
multiple sclerosis (MS) [46], and it has recently been reported that
patients with psoriasis undergoing treatment with anti-IL-23 (guselku-
mab) showed marked improvement in their levels of depression and
anxiety as a secondary analysis of the VOYAGE trial [47], leading to an
exploration of new treatments for MDD.
IL-12 is primarily produced by monocytes and macrophages and
plays a central role in promoting the Th1 response, activating NK cells
to produce IFNg , and driving cell-mediated immunity [48]. Accord-
ingly, we have focused our investigations not only on cytokines but
also on important cellular sources of these cytokines, ie monocytes
and macrophages. The three subsets of monocytes, classical
(CD14brightCD16), intermediate (CD14+CD16+), and non-classical
(CD14negCD16bright), circulate in dynamic equilibrium under steady
state conditions, and only 1% of the classical subset become interme-
diate monocytes to mature later into non-classical monocytes [12]. It
has been proposed that the type of pathogenic stimuli influences the
differentiation of each subset, increasing classical monocytes in bac-
terial infections and non-classical fractions in viral infections or
chronic inflammatory and autoimmune conditions such as MS
[16,48,49]. Our results indicated that the frequency of non-classical
monocytes was increased in patients with higher concentration of IL-te profile in patients with major depressive disorder and suicide
ages by NMDAR and mTOR, EBioMedicine (2019), https://doi.org/
Fig. 3. Ketamine up-regulates M2 gene profile including mTOR pathway related genes. Relative quantification of (a) CCL22, (b) TGM2, (c) IRF4, (d) IRF1, (e) CXCL10, (f) SGK1, (g)
E1F4B and (h) FOXO1 was performed by qPCR. EEF1A1 housekeeping gene was used as reference and fold change was normalized to untreated macrophages. The ketamine-induced
gene profile was compared with untreated macrophages while dexamethasone (0.1mM), IL-4 (40 ng/mL), and LPS (1 ng/mL plus IFN-g [50 ng/mL]) were used as macrophage polar-
ization controls. Each condition was performed with cells from at least 5 independent donors. One-way ANOVA test was performed to compare ketamine conditions to untreated
macrophages and statistical significance is denoted as *p < 0.05; **p < 0.01; ***p < 0.001. Untreated condition: Untd; dexamethasone: DEX.
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correlation was detected with the increased plasma level of IL-12,
suggesting a potential link between IL-12 and non-classical mono-
cytes as was suggested by Chuluundorj et al [16].Please cite this article as: W. Nowak et al., Pro-inflammatory monocy
behaviour and how ketamine induces anti-inflammatory M2 macroph
10.1016/j.ebiom.2019.10.063The exacerbated inflammatory profile of patients with MDD
was also shown by the higher levels of CD86 and CD40 expression
on CD16negCD14bright classical monocytes when compared with
HCs. Increased pro-inflammatory cytokines (IL-6 and IL-12) werete profile in patients with major depressive disorder and suicide
ages by NMDAR and mTOR, EBioMedicine (2019), https://doi.org/
Fig. 4. NMDAR antagonist MK-801, but not the AMPAR antagonist NBQX, induces a similar M2 profile as ketamine, and this phenotype is completely abolished by the inhibition of
the mTOR pathway. Monocyte-derived macrophages were differentiated for 7 days in the presence or absence of the NMDAR antagonist MK-801 (1 and 10 mM) or AMPAR antago-
nist NBQX (1 and 10 mM), and the percentage of (a) MERTK and (b) CD206 was analysed for M2 polarization by flow cytometry. Representative histograms and independent data
are shown. Rapamycin (0.011 nM), added from day 0, was used to evaluate the role of the mTOR pathway in macrophage polarization after 7 days of culture. Viable CD11b+ cells
were analysed for the expression of (c) MERTK, (d) CD206, (e) CD64, and (f) CD163. Each experimental condition includes at least 4 independent donors. Pooled data were graphed
and one-way ANOVA testwas performed accordingly. Statistical significance is denoted as *p < 0.05; **p < 0.01; ***p < 0.001.
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pared with HC when stimulated with LPS. Additionally, the
increased level of intracellular IL-12 in classical monocytes of
patients with MDD reinforces the hypothesis that classicalPlease cite this article as: W. Nowak et al., Pro-inflammatory monocy
behaviour and how ketamine induces anti-inflammatory M2 macroph
10.1016/j.ebiom.2019.10.063monocytes are becoming more activated promoting the transition
to intermediate and finally to non-classical monocytes. These
results clearly demonstrate an increased pro-inflammatory pro-
file in patients with MDD.te profile in patients with major depressive disorder and suicide
ages by NMDAR and mTOR, EBioMedicine (2019), https://doi.org/
Fig. 5. Injection of sub-anaesthetic doses of ketamine modulates circulating myeloid compartment and promotes the differentiation of anti-inflammatory M2 macrophages in vivo.
72 hours after the intraperitoneal injection of sub-anaesthetic doses of ketamine (10 mg/kg) or saline solution, peripheral blood cells, bone marrow, spleen and total leukocytes
from CNS were analysed. Peripheral circulating monocytes were analysed by gating on CD11b+Ly6C+Ly6G by flow cytometry. Ketamine administration significantly reduces (a) the
inflammatory Ly6Chigh monocytes and increases (b) the Ly6Clow monocyte fraction. (c) The absolute number of bone marrow cells as well as (d) the total number of splenocytes was
significantly increased 72 hours after the administration of sub-anaesthetic doses of ketamine compared with control mice. (e) The percentage of tissue resident CD45lowCD11b+
cells in the CNS was similar between groups, but (f) the percentage of hematopoietic CD45highCD11b+F4/80+macrophages was significantly reduced in CNS tissue from ketamine-
treated mice. Furthermore, (g) the percentage of Arginase-1+ macrophages (CD45highCD11b+F4/80+) was significantly increased in the CNS and (h) spleens of ketamine-treated
mice. (i) and (j) BMDM from ketamine-treated or control mice, were differentiated for 7 days in the presence of M-CSF. These BMDMs were harvested and then challenged with 100
ng/ml of LPS for 24 hours. The percentage of (i) CD86+CD206 cells and (j) the mean fluorescence intensity (MFI) of CD36+ pro-inflammatory markers were significantly reduced in
BMDM obtained from ketamine-treated mice. (k) The percentage of CD206+CD86 macrophages was significantly increased in ketamine-treated compared with untreated mice. In-
vivo experiments were performed with at least 45 mice per each condition, and repeated twice. Pooled data were graphed and statistical significance is denoted as *p < 0.05;
**p < 0.01; ***p < 0.001. Student’s t test or one-way ANOVA testwere performed accordingly.
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14 W. Nowak et al. / EBioMedicine 00 (2019) 116Intriguingly, although all patients included in the present study
were hospitalized for suicide behaviour with a severe MDD score, not
all of them had high cytokine levels or a pro-inflammatory cellular
profile. Two possibilities exist: Either inflammation is associated with
only a fraction of these patients, or alternatively, inflammation indi-
cates a particular stage of the disease. A limitation of our study is that
cytokines and monocyte subset proportion could not be controlled
by age, gender, BMI, or medication due to the number of samples; in
order to gain insight into the two possibilities, a longitudinal pro-
spective study is necessary. In this sense, several studies have dem-
onstrated that peripheral immune deregulation may represent an
important pathway for inducing functional and structural brain
changes, specifically in the prefrontal cortex (PFC) and hippocampus
that underpin the pathophysiology of MDD [50,51].
In the last few years, ketamine has emerged as prototype of a
group of rapid-acting antidepressants (RAAD) with a clinical antide-
pressant response starting at 2 h, reaching maximal effect at 24 h,
and lasting up to 7 days after a single infusion, giving ketamine a
very different profile than traditional antidepressants and spurring
an exciting field of research [3,26,52]. The mechanism that leads to
the antidepressant action of ketamine is not completely understood.
To date, two ketamine-induced glutamate neurotransmission
changes appear to be critical to its RAAD effect: (a) A ''transient''
increase in post-synaptic glutamatergic stimulation in the PFC and
(b) a sustained increase in PFC synaptic connectivity [53]. Mechanisti-
cally, ketamine leads to activity-dependant release of brain-derived
neurotrophic factor, activation of mTOR pathway in the CNS, and
increased protein synthesis and synaptic strength [33,53,54].
Ketamine is a racemic mixture comprising equal parts of (R) and
(S) enantiomers, of which (S)-ketamine has been regarded as the
active isomer because of its higher affinity for the NMDA receptor
(34-fold), which pharmacologically explains the 4-fold greater
anaesthetic potency and greater undesirable psychotomimetic side
effects [55]. However, recent studies have shown that (R)-ketamine
has a rapid-onset and sustained antidepressant action without psy-
chotomimetic side effects [5658]. Additionally, it was reported that
its antidepressant effect was independant of mTOR pathway but
involved extracellular signal-regulated kinase (ERK) signalling [59].
These previous findings suggest that mTOR signalling plays a role in
the antidepressant effects of (S)-ketamine meanwhile ERK signalling
plays a role in the antidepressant effects of (R)-ketamine. Neverthe-
less, further detailed studies are needed to better understand the
mechanism of the antidepressant actions of racemic ketamine and
the clinical implication of their enantiomers.
Until now, most research about ketamine focused on neuronal cells,
but the effect of ketamine on innate immune response has just begun,
with a recent clinical study showing a positive correlation between
changes in cytokine levels after ketamine infusion and improvement in
depressive symptoms in treatment-resistant depression [30].
Taking into account the predominant role of the monocyte-macro-
phage lineage in cytokine production as well as tissue infiltration and
homoeostasis, we explored the role of ketamine in reprogramming the
innate immune response and macrophage polarization. Here, we dem-
onstrated that ketamine skewed monocytes into M2c-like macrophages
by augmenting CD163 and MERTK expression, with intermediate levels
of CD64 comparable with the regulatory phenotype driven by dexa-
methasone challenge. Similarly, ketamine was able to reduce macro-
phage activation markers (CD80 and HLA-DR) and dampen cytokine
production induced by LPS, highlighting its anti-inflammatory proper-
ties. The central goal of macrophage biology is to define macrophage
polarization on a molecular basis along with the specific pathways
involved in physiological or pathological processes.
It has been described that in the CNS, ketamine activates NMDAR
and mTOR pathway, inducing an increase of protein synthesis and
synaptic strength [33], but how ketamine programs monocyte and
macrophages to become an anti-inflammatory responder was notPlease cite this article as: W. Nowak et al., Pro-inflammatory monocy
behaviour and how ketamine induces anti-inflammatory M2 macroph
10.1016/j.ebiom.2019.10.063clearly explored. Our results showed that ketamine acts on mono-
cytes by inducing a M2c-like phenotype via the NMDAR and mTOR
pathway but also by promoting a particular gene expression profile
that supports an independant way to induce the M2 program. In
agreements with our results, murine models have also demonstrated
the critical role of the mTOR complex for orchestrating macrophage
polarization [36,60,61]. Remarkably, in vivo administration of keta-
mine at sub-anaesthetic doses promotes reduction of circulating clas-
sical pro-inflammatory monocytes and increase of the arginase-1+
M2 macrophage subset in the spleens and CNS of mice. Of note, to
our knowledge no previous studies in murine models have described
the effects of ketamine alone on spleen size or cellularity, yet our
result showed that sub-anaesthetic doses of ketamine increased total
cellularity in spleen and bone marrow. We speculate that the
increased haematopoiesis may also impact splenic cellularity. How-
ever, ketamine-induced increase in splenocytes must be better stud-
ied in order to understand causality.
In summary, our data suggests that systemic ketamine adminis-
tration biases the immune profile toward an anti-inflammatory
response. This result potentially explains the rapid and sustained
beneficial effect of ketamine in patients with MDD since ketamine
can not only target the neurological system but can also skew the
immune response toward an anti-inflammatory state. Our results
have significant biological implications due to the historical anti-
depressant function of ketamine and its novel role as an anti-inflam-
matory mediator in other inflammatory-based diseases.
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